GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (NAS:SVRA) » Definitions » 3-Year EPS without NRI Growth Rate

Savara (Savara) 3-Year EPS without NRI Growth Rate : 26.90% (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Savara 3-Year EPS without NRI Growth Rate?

Savara's EPS without NRI for the three months ended in Dec. 2023 was $-0.09.

During the past 3 years, the average EPS without NRI Growth Rate was 26.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 30.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 37.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Savara was 60.70% per year. The lowest was -52.60% per year. And the median was 36.10% per year.


Competitive Comparison of Savara's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Savara's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Savara's 3-Year EPS without NRI Growth Rate falls into.



Savara 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Savara  (NAS:SVRA) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Savara 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Savara's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara (Savara) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (NAS:SVRA) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Executives
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
David L Lowrance officer: Chief Financial Officer 422 WILLIAM WALLACE DRIVE, FRANKLIN TN 37064
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Growth Equity Opportunities 17, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Raymond Dennis Pratt officer: Chief Medical Officer 208 E CHASE ST, BALTIMORE MD 21202
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121